This pilot study found that machine learning predicted post acute facility care (PAC) needs with 85% accuracy, demonstrating its feasibility and potential to help prioritize rehabilitation consultations early in hospitalization.
|Articles|August 18, 2012
Biosimilars: Overview of the European Medicines Agency (EMA) Experience
Advertisement
Biosimilars: Overview of the European Medicines Agency (EMA) Experience [Enduring Webcast]
This webcast is brought to you by Amgen.
The faculty for this webcast:
- Described the regulatory pathway for European Medicines Agency (EMA) approval of biosimilars
- Discussed key requirements for biosimilar product approval based on EMA scientific guidelines
- Compared an innovator application versus a biosimilar application data package
- Described the challenges with pharmacovigilence
- Discussed product naming and automatic substitution
- Reviewed approvals, withdrawals, and rejections of biosimilar application submissions to EMA
- Highlighted regulatory pathways established by other countries for biosimilars
Length of webcast: 14 minutes
System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Macintosh®-based attendees
Required: Mac OS® X 10.4.11 (Tiger®) or newer
70576-R1-V1
Advertisement
Related to this article
New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Risankizumab Outperforms Deucravacitinib in Moderate Plaque Psoriasis
5